Month: September 2020

56-54-2, (S)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-vinylquinuclidin-2-yl)methanol is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,56-54-2

To a solution of epi-quinine (232 mg, 0.71 mmol) in DMSO (5 mL) was added LiH (11.1 mg, 1.1 mmol, 1.5 equiv) and the suspension was stirred for 1 h at room temperature. Then 2-chloro-1,10-phenanthroline (181 mg, 0.84 mmol, 1.2 equiv) was added and the mixture was stirred for 18 h at room temperature and 6 h at 80?85 ¡ãC. The cooled mixture was diluted with ethyl acetate (50 mL) and washed with brine (10 ¡Á 15 mL), the solvent was removed in vacuo, and the residue purified on silica gel (CHCl3 / MeOH 10:1) to afford 246 mg (67percent) of white solid.

As the paragraph descriping shows that 56-54-2 is playing an increasingly important role.

Reference£º
Article; Zieliska-Blajet, Mariola; Boratyski, Przemyslaw J.; Sidorowicz, Lukasz; Skarzewski, Jacek; Tetrahedron; vol. 72; 21; (2016); p. 2643 – 2648;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.39069-02-8,2,9-Dibromo-1,10-phenanthroline,as a common compound, the synthetic route is as follows.,39069-02-8

To 1 mL of the solution of silver(I) tetrafluoroborate (1.17 mg, 0.00601 mmol) in dichloromethane was added 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (3.48 mg, 0.00601 mmol), and the mixture was stirred at room temperature for 15 minutes. Then, f23 (2.03 mg, 0.00601 mmol) was added to the reaction solution, which was stirred at 40C for five minutes. The reaction solution was subjected to recrystallization by slow diffusion of dichloromethane-ether and dried to provide 5.40 mg of the complex of the pale yellow crystal. [Show Image] The NMR data of the obtained complex is provided below. 1H NMR (300 MHz, CDCl3) delta 8.50 (brd, 2H), 8.13 (brs, 2H), 7.84 (brd, 2H), 7.62 (brd, 2H), 7.26-7.04 (m, 22H), 6.78 (br, 2H), 1.71 (s, 6H); 31P NMR (122 MHz, CDCl3); 31P NMR (122 MHz, CDCl3) delta -4.9 (d, J (31P-107Ag, 109Ag) = 392, 451 Hz). The composition of the obtained complex was determined according to the same method as in Example 15. The present complex corresponds to the above composition formula (5).

39069-02-8 2,9-Dibromo-1,10-phenanthroline 15448099, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Sumitomo Chemical Company, Limited; EP2360162; (2011); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.103946-54-9,4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid,as a common compound, the synthetic route is as follows.

103946-54-9, Weigh the NH2-C4 dichloro bridge 1mmolAnd 2.2 mmol of 4-methyl 4′-carboxy-2,2′-bipyridine was added to the reaction flask, vacuumed, and protected with nitrogen.Reacted at 40 C for 10 h,After adding KPF630mmol reaction for 2h,Spin dry, extract with dichloromethane (3 ¡Á 150mL), take the organic phase, spin dry into silica gel powder column, separate and purify,The yield was 59%.

103946-54-9 4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid 11127621, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Nanjing University of Posts and Telecommunications; Zhang Yin; Wei Huanjie; Zhang Taiwei; Zhao Qiang; Liu Shujuan; Huang Wei; (11 pag.)CN107880076; (2018); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

100125-12-0, 3,8-Dibromo-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: [Cu(CH3CN)4]ClO4 (32.6 mg, 0.100 mmol) was added to a dichloromethane (DCM) solution (about 10 mL) of BrphenBr (33.6 mg, 0.100 mmol) and BINAP (63.5 mg, 98%, 0.100 mmol) under a stream of dry argon using Schlenk techniques at room temperature. After stirring for 5 h at room temperature, n-hexane was carefully dropped over the DCM solution, and orange-yellow crystals were obtained a few days later in 52.5% yield (67.9 mg)., 100125-12-0

The synthetic route of 100125-12-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Feng, Xiao-Yan; Xin, Xue-Lian; Guo, Ya-Meng; Chen, Ling-Ling; Liang, Yu-Ying; Xu, Min; Li, Xiu-Ling; Polyhedron; vol. 101; (2015); p. 23 – 28;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4568-71-2,3-Benzyl-5-(2-hydroxyethyl)-4-methylthiazol-3-ium chloride,as a common compound, the synthetic route is as follows.

Step A Preparation of 1-(3,4-dimethoxyphenyl)-4-(2-naphthyl)butan-1,4-dione Sodium acetate (2.38 g), 3-benzyl-4-methyl-5(2-hydroxyethyl)thiazolium chloride (3.78 g), 2-naphthaldehyde (10.92 g), 3,4-dimethoxybenzaldehyde (17.43 g), vinylsulfone (7.00 ml) and dimethylformamide (dry DMF, 35 ml) were stirred at room temperature for about 13 days. The reaction mixture was partitioned between chloroform and water and the layers separated. The pooled organic layers were washed with water, dried over anhydrous potassium carbonate and evaporated in vacuo to give about 24.9 g of an oil. The oil was chromatographed to give 1.8 g of crude product which was crystallized from methanol to give 623.2 mg of pure 1-(3,4-dimethoxyphenyl)-4-(2-naphthyl)butan-1,4-dione, m.p. 133¡ã C.

4568-71-2, As the paragraph descriping shows that 4568-71-2 is playing an increasingly important role.

Reference£º
Patent; Merck & Co., Inc.; US4539332; (1985); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4479-74-7, 2,2-Bipyridine-6,6-dicarboxylic Acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

2,2′-Bipyridine-6,6′-dicarboxylic acid (0.37 g,1.5 mmol) in mixture of thionyl chloride (10 ml) and DMF (0.3 ml) wasrefluxed for 2.5 h. Then thionyl chloride was removed, the solid residuewas dissolved in absolute THF (15 ml) and the resulting solution was addedportionwise to a solution of tetraethyl [iminodi(methylene)]bis(phosphonate)(1 g, 3.15 mmol) and Et3N (1 ml) in absolute THF (10 ml). The mixturewas stirred at room temperature for 16 h. Then water (5 ml) was addedand the organic layer was separated, washed with water and dried overanhydrous Na2SO4. The solvent was evaporated to leave dark oil. Thendiethyl ether (5 ml) was added to the oil and the mixture was ground untilprecipitate formation. The precipitate was filtered off, washed with colddiethyl ether and dried in air to afford product 3 as white powder. Yield1 g (79%), mp 116-118C. 1H NMR (600 MHz, CDCl3) delta: 1.19 (t, 12H,CH2Me, 3J 7.0 Hz), 1.36 (t, 12H, CH2Me, 3J 7.0 Hz), 3.94-4.01 (m, 8H,CH2Me), 4.20-4.27 (m, 8H, CH2Me), 4.39 (d, 4H, 2CH2P, 2J 11.1 Hz),4.76 (d, 4H, 2CH2P, 2J 11.2 Hz), 7.85 (d, 2H, 3,3′-CH, 3J 7.5 Hz), 7.97(t, 2H, 4,4′-CH, 3J 7.7 Hz), 8.50 (d, 2H, 5,5′-CH, 3J 7.2 Hz). 13C NMR(100 MHz, CDCl3) delta: 16.2 (d, J 5.1 Hz), 16.3 (d, J 5.0 Hz), 41.3 (d,J 155.9 Hz), 44.5 (d, J 154.7 Hz), 62.2 (d, J 6.0 Hz), 62.6 (d, J 5.7 Hz),122.1, 125.4, 138.2, 152.5, 153.1, 167.5. 31P NMR (162 MHz, CDCl3) delta:2 1.64, 21.65. MS (MALDI-TOF), m/z: 881 [M+K]+. Found (%): C, 45.72;H, 6.51; N, 14.78. Calc. for C32H54N4O14P4 (%): C, 45.61; H, 6.46;N, 14.70., 4479-74-7

The synthetic route of 4479-74-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Farat, Oleg K.; Kharcheva, Anastasia V.; Ioutsi, Vitaliy A.; Borisova, Natalia E.; Reshetova, Marina D.; Patsaeva, Svetlana V.; Mendeleev Communications; vol. 29; 3; (2019); p. 282 – 284;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

6813-38-3, [2,2′-Bipyridine]-4,4′-dicarboxylic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

6813-38-3, A monocarboxylic acid, 4-carboxy-4?-ethyl-2,2?-bipyridine 9 was identified as methyl ester as follows. Isolated mixture of 2 and 9 (Table 4, entry 5) was dissolved in 40 mL methanol, and 1 mL conc. H 2 SO 4 was added. The solution was refluxed for 24h, and then the cooled mixture was neutralized by adding aqueous NaHCO 3 solution. After removal of methanol at reduced pressure, H 2 O was added to the residue, and insoluble dimethyl 2,2′-bipyridine-4,4′-dicarboxylate S7 was filtered off and washed well with H 2 O. The filtrate and washings were combined and extracted with CH 2 Cl 2 . The organic layer was separated, dried with anhydrous Na 2 SO 4 , and the solvent was removed out under a reduced pressure. The colorless oil obtained was identified as 4-ethyl-4?-methoxycarbonyl-2,2?-bipyridine 16by its spectral data. The colorless oil solidified on standing several days in freezer. 4-Ethyl-4?-methoxycarbonyl-2,2?-bipyridine 16: mp 38-40C 1 H NMR (400 MHz, CDCl 3 ,TMS) ppm: 1.32 (3H, t, J=7.6 Hz), 2.76 (2H, q, J=7.6 Hz), 7.20 (1H, dd, J=5.0 Hz, 1.8 Hz), 7.86 (1H, dd, J=5.0 Hz, 1.8 Hz) 8.28 (1H, t, J=0.9 Hz), 8.61 (1H, d, J=5.0 Hz), 8.63 (2H, s), 8.82 (1H, dd, J=5.0 Hz, 0.9 Hz) 8.93 (1H, t, J=0.9 Hz); 13 C NMR (100 MHz, CDCl 3 , TMS) ppm: 14.4, 28.4, 52.7, 120.6, 120.9, 122.7, 123.9, 138.5, 149.3, 149.8, 154.2, 155.2, 157.5, 165.8. IR (ATR, cm -1 ) 3437, 3056, 2967, 2947, 2925, 2882, 2847, 1932, 1721, 1592, 1552, 1460, 1439, 1291, 1230, 1106, 963, 843, 747, 684; MS (EI) m/z(%) 242 (79) [M] + , 241 (96), 184 (100); Anal. Calcd for C 14 H 14 N 2 O 2 : C, 69.41; H, 5.82; N, 11.56. Found: C, 69.31; H, 6.00; N, 11.16.

The synthetic route of 6813-38-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Yamazaki, Shigekazu; Synthetic Communications; vol. 49; 17; (2019); p. 2210 – 2218;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.14162-95-9,4-Bromo-2,2′-bipyridine,as a common compound, the synthetic route is as follows.

In a flame dried 50-mL 3-neck flask fitted with a condenser, a mixture of anthraceneboronic acid 35-7 (522 mg, 0.985 mmol), 4-bromo-2,2?-bipyridine (154 mg, 0.657 mmol), and cesium carbonate (640 mg, 1.97 mmol) in EtOH (15 mL) and water (2 mL) was degassed by refluxing under argon stream for 75 minutes. Then Pd(OAc)2 (29.7 mg, 0.131 mmol) and PPh3 (138 mg, 0.526 mmol) were added in one portion. Refluxing under argon was continued until the reaction was complete in 90 minutes. The reaction mixture was then allowed to cool to room temperature and filtered; the solid residue was rinsed with DCM and MeOH. The filtrate was concentrated in vacuo, and the resulting residue was purified by reversed-phase flash chromatography (C18 190 SiO2, eluted with gradient of 0.09% 58 HCl in 23 MeOH). The pure product was isolated by basification of combined and concentrated fractions with solid 43 NaHCO3 (200 mg) followed by extraction with DCM twice. The combined DCM layers were then dried over MgSO4 and concentrated in vacuo to yield 192 product as a yellow solid (316 mg, 50%).

14162-95-9, 14162-95-9 4-Bromo-2,2′-bipyridine 12087122, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Profusa, Inc.; GAMSEY, Soya; BERNAT, Viachaslau; KUTYAVIN, Alex; CLARY, Jacob William; PRADHAN, Sulolit; (192 pag.)US2018/179233; (2018); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

3779-42-8, 3-Bromo-N,N,N-trimethylpropan-1-aminium bromide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a vigorously-stirred suspension of Compound 5 (80 mg, 0.14 mmol) and K2CO3 (230 mg, 1.7 mmol) in DMF (30 mL) is added (1- bromopropyl) -trimethylammonium bromide (0.3 g, 16.6 mmol) at 50 C. The mixture is stirred at this temperature for 18 h. After removal of the DMF under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (ca. 1L) the crude product is eluted with acetic acid: methanol: water (3: 2: 1, by vol. ). Appropriate fractions are collected and, after evaporation of the solvent under reduced pressure, the residue obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 eluting with n-butanol: water: acetic acid (5: 4: 1, by vol., upper phase). After removal of the solvent from appropriate fractions under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and the solution is passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). After collection of the eluate, solvent is removed under reduced pressure and the residue obtained is dried under high vacuum to yield the dichloride salt as violet crystals. 1H-NMR : 6H (300MZ, CD30D) : 0.75 (T, 3J7. 5 Hz, 3 H), 1.05-1. 20 (m, 14 H), 1.45- 1.50 (m, 2 H), 2.05-2. 15 (m, 4 H), 2.15-2. 20 (m, 2 H), 2.95 (s, 18 H), 3.35-3. 45 (m, 4 H), 3.95 (T, 3J7. 5 Hz, 4 H), 4.55 (t, 3J7. 5 Hz, 2 H), 6. 85 (m, 1 H), 7.35 (m, 2 H), 8.85-8. 90,9. 15-9.20, (3 X M, 8 H), 10.10 (s, 2 H).

3779-42-8, The synthetic route of 3779-42-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; DESTINY PHARMA LIMITED; SOLVIAS AG; WO2004/56828; (2004); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

[00134] To a solution of 4-(pyren-1 -yl)butanal (37 mg, 0.14 mmol) in 0.9 ml_ DCE, Boc3Cyclam (45 mg, 0.09 mmol) was added and stirred together with 4A molecular sieves for 2 h under nitrogen atmosphere. To this solution sodium triacetoxyborohydride (38 mg, 0.18 mmol) was added and the reaction mixture was allowed to stir at ambient temperature over 24 h under nitrogen atmosphere. Subsequently, the reaction mixture was diluted with sodium bicarbonate and extracted with DCM. The extract was purified by flash chromatography with 35% ethyl acetate/hexanes to give the product (43 mg, 63%); 1 H NMR (400 MHz, CDCb) delta 8.29 (d, J = 9.3 Hz, 1H), 8.21 – 7.98 (m, 7H), 7.88 (d, J = 7.8 Hz, 1H), 3.46 – 3.09 (m, 14H), 2.59 (s, 2H), 2.50 – 2.33 (m, 4H), 1.93 – 1.74 (m, 4H), 1.73 – 1.58 (m, 4H), 1.53 – 1.41 (m, 27H); 13C NMR (100 MHz, CDCb) delta 155.69, 136.80, 131.44, 130.91, 129.80, 128.58, 127.52, 127.24, 127.20, 126.57, 125.81, 125.1 1, 125.05, 124.86, 124.81, 124.67, 123.40, 79.55, 79.36, 55.42, 48.69, 48.55, 47.30, 46.90, 46.62, 45.69, 33.54, 29.85, 29.72, 28.56, 28.50, 26.79; LRMS (ESI+) m/z calc’d for CHesN- e [M + H]+ 757.49, found 757.69., 170161-27-0

As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.

Reference£º
Patent; THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO; GUNNING, Patrick Thomas; KRASKOUSKAYA, Dziyana; CABRAL, Aaron; MURCAR-EVANS, Bronte; TOUTAH, Krimo; DE ARAUJO, Elvin; (141 pag.)WO2019/68177; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI